137 related articles for article (PubMed ID: 22068911)
1. The influence of interleukin-32γ on osteoclastogenesis with a focus on fusion-related genes.
Kim YG; So MW; Koo BS; Chang EJ; Song SJ; Lee CK; Yoo B
J Clin Immunol; 2012 Feb; 32(1):201-6. PubMed ID: 22068911
[TBL] [Abstract][Full Text] [Related]
2. NFATc1 induces osteoclast fusion via up-regulation of Atp6v0d2 and the dendritic cell-specific transmembrane protein (DC-STAMP).
Kim K; Lee SH; Ha Kim J; Choi Y; Kim N
Mol Endocrinol; 2008 Jan; 22(1):176-85. PubMed ID: 17885208
[TBL] [Abstract][Full Text] [Related]
3. Induction of DC-STAMP by alternative activation and downstream signaling mechanisms.
Yagi M; Ninomiya K; Fujita N; Suzuki T; Iwasaki R; Morita K; Hosogane N; Matsuo K; Toyama Y; Suda T; Miyamoto T
J Bone Miner Res; 2007 Jul; 22(7):992-1001. PubMed ID: 17402846
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.
Kalliolias GD; Zhao B; Triantafyllopoulou A; Park-Min KH; Ivashkiv LB
Arthritis Rheum; 2010 Feb; 62(2):402-13. PubMed ID: 20112358
[TBL] [Abstract][Full Text] [Related]
5. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes.
Kim YG; Lee CK; Oh JS; Kim SH; Kim KA; Yoo B
Arthritis Rheum; 2010 Feb; 62(2):515-23. PubMed ID: 20112365
[TBL] [Abstract][Full Text] [Related]
6. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
[TBL] [Abstract][Full Text] [Related]
7. High glucose inhibits receptor activator of nuclear factor‑κB ligand-induced osteoclast differentiation via downregulation of v‑ATPase V0 subunit d2 and dendritic cell‑specific transmembrane protein.
Xu J; Yue F; Wang J; Chen L; Qi W
Mol Med Rep; 2015 Feb; 11(2):865-70. PubMed ID: 25352342
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.
Jules J; Zhang P; Ashley JW; Wei S; Shi Z; Liu J; Michalek SM; Feng X
J Biol Chem; 2012 May; 287(19):15728-38. PubMed ID: 22416138
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).
Odkhuu E; Koide N; Haque A; Tsolmongyn B; Naiki Y; Hashimoto S; Komatsu T; Yoshida T; Yokochi T
Immunol Lett; 2012 Feb; 142(1-2):34-40. PubMed ID: 22193059
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
[TBL] [Abstract][Full Text] [Related]
12. Esculetin attenuates receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation through c-Fos/nuclear factor of activated T-cells c1 signaling pathway.
Baek JM; Park SH; Cheon YH; Ahn SJ; Lee MS; Oh J; Kim JY
Biochem Biophys Res Commun; 2015 May; 461(2):334-41. PubMed ID: 25887803
[TBL] [Abstract][Full Text] [Related]
13. Aconine inhibits RANKL-induced osteoclast differentiation in RAW264.7 cells by suppressing NF-κB and NFATc1 activation and DC-STAMP expression.
Zeng XZ; He LG; Wang S; Wang K; Zhang YY; Tao L; Li XJ; Liu SW
Acta Pharmacol Sin; 2016 Feb; 37(2):255-63. PubMed ID: 26592521
[TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
15. Gymnasterkoreayne F inhibits osteoclast formation by suppressing NFATc1 and DC-STAMP expression.
Kim HJ; Hong J; Jung JW; Kim TH; Kim JA; Kim YH; Kim SY
Int Immunopharmacol; 2010 Nov; 10(11):1440-7. PubMed ID: 20831919
[TBL] [Abstract][Full Text] [Related]
16. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
17. The fungal metabolite (+)-terrein abrogates osteoclast differentiation via suppression of the RANKL signaling pathway through NFATc1.
Nakagawa S; Omori K; Nakayama M; Mandai H; Yamamoto S; Kobayashi H; Sako H; Sakaida K; Yoshimura H; Ishii S; Ibaragi S; Hirai K; Yamashiro K; Yamamoto T; Suga S; Takashiba S
Int Immunopharmacol; 2020 Jun; 83():106429. PubMed ID: 32222639
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
[TBL] [Abstract][Full Text] [Related]
19. Regulators of osteoclast differentiation and cell-cell fusion.
Miyamoto T
Keio J Med; 2011; 60(4):101-5. PubMed ID: 22200633
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]